AYTU BIOPHARMA, INC
Financial highlights
| Metric | FY 06/30/25 | FY 06/30/24 | FY 06/30/23 | FY 06/30/22 | FY 01/26/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $66.4M | $65.2M | $107.4M | $96.7M | — |
| Cost of revenue | $20.6M | $16.1M | $40.8M | $44.4M | — |
| Gross profit | $45.8M | $49.1M | $66.6M | $52.3M | — |
| Research and development | $1.3M | $2.8M | $4.1M | $12.7M | — |
| Operating expenses | $53.7M | $50.6M | $83.7M | $162.2M | — |
| Operating income | -$7.8M | -$1.6M | -$17.1M | -$109.9M | — |
| Interest expense | $3.7M | $5.1M | $5.0M | — | — |
| Pretax income | -$13.7M | -$10.4M | -$17.1M | -$108.9M | — |
| Income tax expense | $437,000 | $2.1M | $0 | -$110,000 | — |
| Net income | -$13.6M | -$15.8M | -$17.1M | -$108.8M | — |
| Balance Sheet | |||||
| Cash and equivalents | $31.0M | $20.0M | $23.0M | $19.4M | — |
| Current assets | $79.2M | $61.9M | $72.8M | $59.9M | — |
| Total assets | $124.2M | $118.1M | $136.5M | $137.6M | — |
| Current liabilities | $63.1M | $62.2M | $69.0M | $64.4M | — |
| Total liabilities | — | — | $97.1M | $93.3M | — |
| Total debt | $13.0M | $13.0M | $15.0M | — | $600,000 |
| Stockholders' equity | $19.0M | $27.7M | $39.4M | $44.3M | — |
| Cash Flow Statement | |||||
| Cash from operations | -$1.9M | -$1.4M | -$5.1M | -$28.8M | — |
| Depreciation and amortization | $5.4M | $8.3M | $8.8M | $10.1M | — |
| Stock-based compensation | $576,000 | $2.4M | $6.0M | $5.2M | — |
| Capital expenditure | $228,000 | $329,000 | — | $0 | — |
| Free cash flow | -$2.2M | -$1.7M | — | -$28.8M | — |
| Impairments | $8.3M | $0 | $5.7M | $75.5M | — |
Shares outstanding 10.7M · Free float 95.3%
Annual filing data through FY ended June 30, 2025; float as of July 13, 2026.